Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Appl Immunohistochem Mol Morphol ; 21(5): 452-9, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23060305

ABSTRACT

Colonic inertia is a frustrating motility disorder to patients, clinicians, and pathologists. The pathogenesis is largely unknown. The aims of this study were to: (1) characterize the expression of smoothelin, a novel smooth muscle-specific contractile protein expressed only by terminally differentiated smooth muscle cells, in the normal gastrointestinal (GI) tract; and (2) determine whether smoothelin is aberrantly expressed in patients with colonic inertia. A total of 57 resections of the normal GI tract (distal esophagus to left colon) were obtained from patients without GI motor dysfunction. Sixty-one colon resections were obtained from patients with a clinical diagnosis of colonic inertia. Smoothelin immunostaining was conducted on full-thickness tissue sections. In the nondysmotile controls, strong and diffuse cytoplasmic staining for smoothelin was observed in both the inner circular and outer longitudinal layers of the muscularis propria (MP) throughout the entire GI tract. The muscularis mucosae (MM) and muscular vessel walls were either completely negative or only patchily and weakly stained. The 1 exception to this pattern was observed in the distal esophagus, in which the MM was also diffusely and strongly stained. In cases with colonic inertia, a moderate to marked reduction of smoothelin immunoreactivity was observed in 15 of 61 (24.6%) colon resections, selectively seen in the outer layer of the MP. The data demonstrate that smoothelin is differentially expressed in the MP and MM of the normal GI tract and suggest that defective smoothelin expression may play a role in the pathogenesis of colonic inertia in a subset of patients.


Subject(s)
Constipation/diagnosis , Cytoskeletal Proteins/metabolism , Esophageal Motility Disorders/diagnosis , Gastrointestinal Tract/pathology , Mucous Membrane/metabolism , Muscle Proteins/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Constipation/pathology , Esophageal Motility Disorders/pathology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Mucous Membrane/pathology , Muscle Contraction , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , Retrospective Studies , Young Adult
2.
Immunity ; 33(4): 607-19, 2010 Oct 29.
Article in English | MEDLINE | ID: mdl-20888269

ABSTRACT

Mammalian noncoding microRNAs (miRNAs) are a class of gene regulators that have been linked to immune system function. Here, we have investigated the role of miR-155 during an autoimmune inflammatory disease. Consistent with a positive role for miR-155 in mediating inflammatory responses, Mir155(-/-) mice were highly resistant to experimental autoimmune encephalomyelitis (EAE). miR-155 functions in the hematopoietic compartment to promote the development of inflammatory T cells including the T helper 17 (Th17) cell and Th1 cell subsets. Furthermore, the major contribution of miR-155 to EAE was CD4(+) T cell intrinsic, whereas miR-155 was also required for optimum dendritic cell production of cytokines that promoted Th17 cell formation. Our study shows that one aspect of miR-155 function is the promotion of T cell-dependent tissue inflammation, suggesting that miR-155 might be a promising therapeutic target for the treatment of autoimmune disorders.


Subject(s)
CD4-Positive T-Lymphocytes/physiology , Encephalomyelitis, Autoimmune, Experimental/etiology , MicroRNAs/physiology , Animals , Cells, Cultured , Encephalomyelitis, Autoimmune, Experimental/immunology , Glycoproteins/immunology , Hypersensitivity, Delayed/immunology , Interferon-gamma/physiology , Interleukin-17/physiology , Mice , Mice, Inbred C57BL , Myelin-Oligodendrocyte Glycoprotein , Peptide Fragments/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...